Ischemic Stroke, AcuteNCT06028802
CT Clock Tool Feasibility Study
An observational study of Ischemic Stroke, Acute, run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
Interruption of blood supply to the brain from a blocked blood vessel causes ischaemic stroke. This leads to symptoms relating to the areas of brain affected. For example, people with stroke may suddenly have trouble moving their arms, legs or face, and may find it hard to speak or lose consciousness. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke, Acute
- What is being tested?
- CT Clock Tool measurement
- How many people
- 35 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 Oct 2023to 25 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Investigators will recruit adult patients presenting acutely to the emergency department with symptoms of stroke, where non-enhanced brain CT excludes haemorrhage and other structural causes for symptoms (i.e. ischaemic stroke is the most likely diagnosis).
Who may be able to join
- With and without a known time of stroke onset.
- With a stroke severity score (NIHSS) >4
- With suspected anterior or posterior circulation ischaemic stroke.
- Over 18 years of age with no upper limit.
- Patients with and without concurrently acquired CTP imaging (acquired only for potential thrombectomy candidates, approximately 20%)
- Patients able to provide informed consent (including witnessed consent when loss of functional ability is evident, e.g. upper limb weakness in dominant hand or visual loss).
Who cannot join
- With a suspected lacunar syndrome (i.e. pure motor stroke, pure sensory stroke, mixed sensorimotor stroke [without cortical signs], ataxic hemiparesis, dysarthria-clumsy hand syndrome).
- Where CT brain imaging demonstrates a non-ischaemic cause for stroke symptoms, e.g. brain haemorrhage, tumour or other relevant structural abnormality.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Feasibility Study of the CT Clock Tool for Estimating Onset Time of Ischaemic Stroke
Interruption of blood supply to the brain from a blocked blood vessel causes ischaemic stroke. This leads to symptoms relating to the areas of brain affected. For example, people with stroke may suddenly have trouble moving their arms, legs or face, and may find it hard to speak or lose consciousness. There are treatments available to open up the blocked blood vessel:
- Thrombolysis involves injecting a medicine to break down the blood clot causing the blockage.
- Thrombectomy means pulling the blood clot out through a tiny tube placed within the blood vessel.
Read more
Both treatments can help restore blood supply to the brain and reverse the symptoms caused by stroke. These treatments are usually only offered when there is a clear onset time for stroke symptoms. However, for around 20% of strokes, the time of onset is unknown. Patients may wake up with symptoms, be confused or be found collapsed.
So that treatment can be available to more people, the investigators have developed a method to estimate when an ischaemic stroke began, the CT Clock Tool. This method involves taking measurements from the brain imaging that most patients with stroke routinely get on arrival at hospital (CT or CAT scanning). In other words, no extra tests are needed to use the method; the investigators seek to make better use of existing tests.
In this study, the aim is to understand whether it is feasible to use the CT Clock Tool method in the real world. For example, can doctors correctly use the tool during their normal work to produce accurate estimates for the onset time of stroke? The results of this study will be used to plan a future clinical trial for testing the safety of the CT Clock Tool when it is used to treat patients.
Read the detailed description
Background
Stroke is a major health concern worldwide causing high rates of disability and death. Most strokes (approximately 85%) are cause by ischaemia following blockage to an arterial blood vessel. Two effective treatments are available that can remove the vessel blockage and thus reduce the rates of both disability and death after stroke. However, both treatments have time-limits for safe delivery. Thrombolysis uses an injected medicine to break down the blood clot and must be used within 4.5 hours of stroke onset (the European licensing time limit for alteplase). Thrombectomy is a surgical procedure that involves pulling the clot out using a catheter placed inside the artery and is usually limited to 6 hours from stroke onset.
Unfortunately, for approximately 20% of patients with ischaemic stroke, the time of symptom onset is not known, usually because patients wake with symptoms or are found collapsed. Such patients have traditionally been denied treatment, but recent research has shown that advanced brain imaging methods (for example CT perfusion or MRI) can be used to identify patients who can still safely be treated in the absence of a known onset time for stroke. However, these advanced imaging methods are not widely available for acute stroke assessment, especially outside major treatment centres in developed nations. For example, it remains difficult in Scotland to offer advanced brain imaging to all who might need it. Plain (non-enhanced) CT is much more widely available and is the standard immediate assessment method for most patients with stroke worldwide.
As ischaemic stroke progresses, injured brain slowly begins to change on plain CT and the ischaemic lesion becomes more and more pronounced with greater oedema and swelling. These changes are seen as a darkening of tissue, indicating a decrease in CT attenuation.
The investigators have developed a method for estimating time of ischaemic stroke onset for individual patients that uses only attenuation measurements of plain CT brain imaging, the CT Clock Tool.
Rationale
The proposed CT Clock Tool method for estimating the time of stroke onset (and thus clarifying individual patient eligibility for effective treatment) is significantly simpler to use in the acute setting than the advanced methods currently available (CT perfusion or MRI).
The CT Clock Tool can provide specific time estimates for a given patient. These estimates are derived from simple measurements of brain that can be manually acquired from non-enhanced CT scans within seconds, no other imaging or specialist viewing software is required. Specifically, users (for example stroke clinicians or radiologists) measure the attenuation of any visible ischaemic lesion and of the equivalent normal brain to derive a CT attenuation ratio (attenuation of ischaemic brain ÷ attenuation of normal brain).
Initial testing shows that an attenuation ratio greater than 0.82 is highly predictive of a stroke onset to CT time less than 4.5 hours (i.e. within the European time limit for thrombolysis with alteplase). At this threshold, the CT Clock Tool is 97% sensitive and 83% specific for correctly classifying patients who are within 4.5 hours of stroke symptom onset. In addition, the investigators have tested associations between the appearances of non-enhanced CT and CT perfusion (CTP) when both are acquired at the same time. The CT attenuation ratio was compared with CTP appearances that indicate affected brain tissue is likely to remain viable. In other words, and in the absence of CTP, a CT attenuation ratio greater than 0.87 is 86% sensitive and 91% specific for identifying brain tissue that remains viable (and is therefore most likely to benefit from treatment).
The longer-term aim is to incorporate the CT Clock Tool into routine clinical care, especially in centres that cannot provide alternative or advanced methods to assess patient eligibility for acute treatment.
This current study seeks to provide a first prospective clinical feasibility evaluation to assess the practicalities of using the method in real time and to evaluate the potential impact on clinical care. The results of the present analysis will inform the design of a future randomised-controlled trial to evaluate whether the CT Clock Tool can safely be used to determine the eligibility of patients for treatment with thrombolysis and/or thrombectomy where time of stroke onset is unknown or is delayed.
- Conditions
- Ischemic Stroke, Acute
- Being tested
- CT Clock Tool measurement
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CT Clock Tool measurementDiagnostic test
Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
| Study group | Role | What they receive |
|---|---|---|
| Visible lesion | Patients where an ischaemic lesion is visible on non-enhanced CT acquired at baseline. Receives: Diagnostic Test: CT Clock Tool measurement | |
| Non-visible lesion | Patients where an ischaemic lesion is not visible on non-enhanced CT acquired at baseline. Receives: Diagnostic Test: CT Clock Tool measurement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of front-line clinicians (stroke clinicians and radiologists) using the CT Clock Tool method during routine care
Proportion of cases where a front-line clinician successfully uses the CT Clock Tool method in the acute setting, i.e. acquires CT measurements (regardless of result)
Measured: CT Clock Tool measurements to be acquired on the day of patient admission (baseline)
Secondary outcomes (5)
Comparison of stroke onset time estimates provided by front-line clinicians using the CT Clock Tool with actual elapsed time
Accuracy of stroke onset time estimates - absolute error of time estimates, proportion over versus under calling time
Measured: Baseline
Diagnostic accuracy of these time estimates for determining treatment eligibility relative to standard thrombolysis and thrombectomy limits (4.5 and 6 hours, respectively)
Sensitivity, specificity, positive and negative predictive values for the CT Clock Tool with reference to thrombolysis and thrombectomy time limits. Including sensitivity analyses for those with and without visible lesions, with differing stroke severity, and with and without advanced imaging at baseline.
Measured: Baseline
Whether estimates of brain tissue viability correlate with equivalent CTP findings
Proportion of cases where tissue viability estimates of the CT Clock Tool agree with CTP indicators for tissue viability
Measured: Baseline
User experience of the CT Clock Tool on a (Likert) satisfaction scale
Ease of use for finding/estimating the location of lesions and making measurements. Each assessed on a scale from 1 (easy) to 5 (hard), i.e. lower scores are better.
Measured: Baseline
Inter-rater agreement
For CT attenuation measurements and the respective time and tissue viability estimates derived from different front-line clinician measurements of the same CT
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2023
- Study start26 Oct 2023
- Primary completion25 Oct 2024
- Study completion25 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Ischemic Stroke, AcuteStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Collaborators
- NHS Lothian
- Responsible party
- Sponsor
- Investigators
- Grant Mair, MD, Principal investigator, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06028802
- Sponsor's protocol ID
- AC23097
- Other IDs
- MRC/IAA/003, 330583
- Status last verified
- Nov 2024
- First submitted
- 25 Aug 2023
- Last updated
- 8 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymised non-imaging data (demographics, stroke severity, stroke subtype, CT imaging features, final diagnosis) will be made openly available using the University of Edinburgh's DataShare platform, https://datashare.ed.ac.uk/.
Publications
Mair G, Alzahrani A, Lindley RI, Sandercock PAG, Wardlaw JM. Feasibility and diagnostic accuracy of using brain attenuation changes on CT to estimate time of ischemic stroke onset. Neuroradiology. 2021 Jun;63(6):869-878. doi: 10.1007/s00234-020-02591-w. Epub 2020 Oct 30.
PubMed 33128140Alzahrani A, Zhang X, Albukhari A, Wardlaw JM, Mair G. Assessing Brain Tissue Viability on Nonenhanced Computed Tomography After Ischemic Stroke. Stroke. 2023 Feb;54(2):558-566. doi: 10.1161/STROKEAHA.122.041241. Epub 2023 Jan 5.
PubMed 36601950
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study of the CT Clock Tool for Estimating Onset Time of Ischaemic Stroke
- ClinicalTrials.gov ID
- NCT06028802
- Acronym / sponsor ID
- AC23097
- Conditions
- Ischemic Stroke, Acute
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Collaborators
- NHS Lothian
- Study start
- 26 Oct 2023 (actual)
- Primary completion
- 25 Oct 2024 (actual)
- Study completion
- 25 Oct 2024 (actual)
- First posted
- 8 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Interruption of blood supply to the brain from a blocked blood vessel causes ischaemic stroke. This leads to symptoms relating to the areas of brain affected. For example, people with stroke may suddenly have trouble moving their arms, legs or face, and may find it hard to speak or lose consciousness. There are treatments available to open up the blocked blood vessel:
- Thrombolysis involves injecting a medicine to break down the blood clot causing the blockage.
- Thrombectomy means pulling the blood clot out through a tiny tube placed within the blood vessel.
Both treatments can help restore blood supply to the brain and reverse the symptoms caused by stroke. These treatments are usually only offered when there is a clear onset time for stroke symptoms. However, for around 20% of strokes, the time of onset is unknown. Patients may wake up with symptoms, be confused or be found collapsed.
So that treatment can be available to more people, the investigators have developed a method to estimate when an ischaemic stroke began, the CT Clock Tool. This method involves taking measurements from the brain imaging that most patients with stroke routinely get on arrival at hospital (CT or CAT scanning). In other words, no extra tests are needed to use the method; the investigators seek to make better use of existing tests.
In this study, the aim is to understand whether it is feasible to use the CT Clock Tool method in the real world. For example, can doctors correctly use the tool during their normal work to produce accurate estimates for the onset time of stroke? The results of this study will be used to plan a future clinical trial for testing the safety of the CT Clock Tool when it is used to treat patients.
Detailed description
Background
Stroke is a major health concern worldwide causing high rates of disability and death. Most strokes (approximately 85%) are cause by ischaemia following blockage to an arterial blood vessel. Two effective treatments are available that can remove the vessel blockage and thus reduce the rates of both disability and death after stroke. However, both treatments have time-limits for safe delivery. Thrombolysis uses an injected medicine to break down the blood clot and must be used within 4.5 hours of stroke onset (the European licensing time limit for alteplase). Thrombectomy is a surgical procedure that involves pulling the clot out using a catheter placed inside the artery and is usually limited to 6 hours from stroke onset.
Unfortunately, for approximately 20% of patients with ischaemic stroke, the time of symptom onset is not known, usually because patients wake with symptoms or are found collapsed. Such patients have traditionally been denied treatment, but recent research has shown that advanced brain imaging methods (for example CT perfusion or MRI) can be used to identify patients who can still safely be treated in the absence of a known onset time for stroke. However, these advanced imaging methods are not widely available for acute stroke assessment, especially outside major treatment centres in developed nations. For example, it remains difficult in Scotland to offer advanced brain imaging to all who might need it. Plain (non-enhanced) CT is much more widely available and is the standard immediate assessment method for most patients with stroke worldwide.
As ischaemic stroke progresses, injured brain slowly begins to change on plain CT and the ischaemic lesion becomes more and more pronounced with greater oedema and swelling. These changes are seen as a darkening of tissue, indicating a decrease in CT attenuation.
The investigators have developed a method for estimating time of ischaemic stroke onset for individual patients that uses only attenuation measurements of plain CT brain imaging, the CT Clock Tool.
Rationale
The proposed CT Clock Tool method for estimating the time of stroke onset (and thus clarifying individual patient eligibility for effective treatment) is significantly simpler to use in the acute setting than the advanced methods currently available (CT perfusion or MRI).
The CT Clock Tool can provide specific time estimates for a given patient. These estimates are derived from simple measurements of brain that can be manually acquired from non-enhanced CT scans within seconds, no other imaging or specialist viewing software is required. Specifically, users (for example stroke clinicians or radiologists) measure the attenuation of any visible ischaemic lesion and of the equivalent normal brain to derive a CT attenuation ratio (attenuation of ischaemic brain ÷ attenuation of normal brain).
Initial testing shows that an attenuation ratio greater than 0.82 is highly predictive of a stroke onset to CT time less than 4.5 hours (i.e. within the European time limit for thrombolysis with alteplase). At this threshold, the CT Clock Tool is 97% sensitive and 83% specific for correctly classifying patients who are within 4.5 hours of stroke symptom onset. In addition, the investigators have tested associations between the appearances of non-enhanced CT and CT perfusion (CTP) when both are acquired at the same time. The CT attenuation ratio was compared with CTP appearances that indicate affected brain tissue is likely to remain viable. In other words, and in the absence of CTP, a CT attenuation ratio greater than 0.87 is 86% sensitive and 91% specific for identifying brain tissue that remains viable (and is therefore most likely to benefit from treatment).
The longer-term aim is to incorporate the CT Clock Tool into routine clinical care, especially in centres that cannot provide alternative or advanced methods to assess patient eligibility for acute treatment.
This current study seeks to provide a first prospective clinical feasibility evaluation to assess the practicalities of using the method in real time and to evaluate the potential impact on clinical care. The results of the present analysis will inform the design of a future randomised-controlled trial to evaluate whether the CT Clock Tool can safely be used to determine the eligibility of patients for treatment with thrombolysis and/or thrombectomy where time of stroke onset is unknown or is delayed.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Visible lesion | – | Diagnostic Test: CT Clock Tool measurementPatients where an ischaemic lesion is visible on non-enhanced CT acquired at baseline. |
| Non-visible lesion | – | Diagnostic Test: CT Clock Tool measurementPatients where an ischaemic lesion is not visible on non-enhanced CT acquired at baseline. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Investigators will recruit adult patients presenting acutely to the emergency department with symptoms of stroke, where non-enhanced brain CT excludes haemorrhage and other structural causes for symptoms (i.e. ischaemic stroke is the most likely diagnosis).
Key inclusion criteria (6 listed)
- With and without a known time of stroke onset.
- With a stroke severity score (NIHSS) >4
- With suspected anterior or posterior circulation ischaemic stroke.
- Over 18 years of age with no upper limit.
- Patients with and without concurrently acquired CTP imaging (acquired only for potential thrombectomy candidates, approximately 20%)
Key exclusion criteria (2 listed)
- With a suspected lacunar syndrome (i.e. pure motor stroke, pure sensory stroke, mixed sensorimotor stroke [without cortical signs], ataxic hemiparesis, dysarthria-clumsy hand syndrome).
- Where CT brain imaging demonstrates a non-ischaemic cause for stroke symptoms, e.g. brain haemorrhage, tumour or other relevant structural abnormality.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CT Clock Tool measurementRatio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain. | Diagnostic test | Non-visible lesion, Visible lesion |
Primary outcome
Feasibility of front-line clinicians (stroke clinicians and radiologists) using the CT Clock Tool method during routine care
Time frame: CT Clock Tool measurements to be acquired on the day of patient admission (baseline)
Proportion of cases where a front-line clinician successfully uses the CT Clock Tool method in the acute setting, i.e. acquires CT measurements (regardless of result)
5 secondary outcomes
Comparison of stroke onset time estimates provided by front-line clinicians using the CT Clock Tool with actual elapsed time
Time frame: Baseline
Diagnostic accuracy of these time estimates for determining treatment eligibility relative to standard thrombolysis and thrombectomy limits (4.5 and 6 hours, respectively)
Time frame: Baseline
Whether estimates of brain tissue viability correlate with equivalent CTP findings
Time frame: Baseline
User experience of the CT Clock Tool on a (Likert) satisfaction scale
Time frame: Baseline
Inter-rater agreement
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2024.
- Background: PubMed 33128140Mair G, Alzahrani A, Lindley RI, Sandercock PAG, Wardlaw JM. Feasibility and diagnostic accuracy of using brain attenuation changes on CT to estimate time of ischemic stroke onset. Neuroradiology. 2021 Jun;63(6):869-878. doi: 10.1007/s00234-020-02591-w. Epub 2020 Oct 30.
- Background: PubMed 36601950Alzahrani A, Zhang X, Albukhari A, Wardlaw JM, Mair G. Assessing Brain Tissue Viability on Nonenhanced Computed Tomography After Ischemic Stroke. Stroke. 2023 Feb;54(2):558-566. doi: 10.1161/STROKEAHA.122.041241. Epub 2023 Jan 5.
- Study website, will include results when available.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymised non-imaging data (demographics, stroke severity, stroke subtype, CT imaging features, final diagnosis) will be made openly available using the University of Edinburgh's DataShare platform, https://datashare.ed.ac.uk/.
Related trials for Ischemic Stroke, Acute
RecruitingPhase 3
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Ischemic Stroke
Not yet recruiting
Short-Term External Trigeminal Nerve Stimulation for Acute Ischemic Stroke: A Sham-Controlled Trial
Acute Ischemic Stroke
Not yet recruitingPhase 1
ARTEMIS: UC-MSCs After Mechanical Thrombectomy for Acute Ischemic Stroke
Acute Ischemic Stroke
Not yet recruitingPhase 3
Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
Acute Ischemic Stroke, Large Vessel Occlusion
Active, not recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
Ischemic Stroke, Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Grant Mair, MD principal investigator
University of Edinburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemic Stroke, Acute, run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of front-line clinicians (stroke clinicians and radiologists) using the CT Clock Tool method during routine care (time frame: CT Clock Tool measurements to be acquired on the day of patient admission (baseline)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06028802, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2024.